Rivastigmine in the Treatment of Dementia: From the Symptomatic Effect to Neuroprotection

Simple item page
dc.creatorN. N, Abdullayeva
dc.creatorA. A, Kasimov
dc.creatorS. N, Bozorova
dc.creatorG. E , Jumanova
dc.date2023-06-30
dc.date.accessioned2023-08-21T09:05:13Z
dc.date.available2023-08-21T09:05:13Z
dc.descriptionDementia is a hot topic today, largely as a result of the ageing of the population. One of the most common causes of dementia is Alzheimer's disease (AD). This disease, which is classified as a primary degenerative dementia, is characterized by a progressive decline in cognitive functions, primarily memory, and the development of behavioral disorders.  en-US
dc.formatapplication/pdf
dc.identifierhttps://univerpubl.com/index.php/scholastic/article/view/2253
dc.identifier.urihttp://dspace.umsida.ac.id/handle/123456789/22114
dc.languageeng
dc.publisherUniver Publishingen-US
dc.relationhttps://univerpubl.com/index.php/scholastic/article/view/2253/1961
dc.sourceScholastic: Journal of Natural and Medical Education; Vol. 2 No. 6 (2023): Scholastic: Journal of Natural and Medical Education; 266-273en-US
dc.subjectdementiaen-US
dc.subjectmild cognitive impairmenten-US
dc.subjecttreatmenten-US
dc.subjectrivastigmineen-US
dc.titleRivastigmine in the Treatment of Dementia: From the Symptomatic Effect to Neuroprotectionen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
Files
Collections
Scholastic: Journal of Natural and Medical Education